Press Releases April 15, 2026 08:00 PM

Balchem Corporation Announces Quarterly Conference Call for First Quarter 2026 Financial Results on April 30, 2026

Balchem Announces Q1 2026 Earnings Conference Call Scheduled for April 30

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BCPC

Balchem Corporation will release its first quarter 2026 financial results before the market opens on April 30, 2026, followed by a conference call hosted by its CEO and CFO to discuss the results. Balchem operates in three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, delivering specialty ingredients globally across various industries including food, pharmaceuticals, animal health, and agriculture.

Balchem Corporation Announces Quarterly Conference Call for First Quarter 2026 Financial Results on April 30, 2026
BCPC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Balchem schedules Q1 2026 earnings release and conference call for April 30, 2026.
  • The company operates in diversified segments impacting nutrition, pharmaceuticals, animal health, and specialty chemicals sectors.
  • Investors and analysts are invited to participate via live webcast or phone, with replay available for a year.

MONTVALE, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Thursday, April 30, 2026, at 11:00 AM Eastern Time (ET) to review first quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call.

First quarter results will be published prior to the market opening on Thursday, April 30, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call.

Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing 800-715-9871 (toll free USA/Canada), +1-646-307-1963 (USA/International) or 647-932-3411 (Canada/Toronto), five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/169585269. The conference call will be available for replay shortly after the conclusion of the call https://events.q4inc.com/attendee/169585269 for one year.  

About Balchem Corporation

Balchem Corporation develops, manufactures, and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement, and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.

Contact:Jacqueline Yarmolowicz, Executive Assistant Telephone: 845-326-5600 E-mail: jyarmolowicz@balchem.com



Risks

  • Potential fluctuations in demand within the food, supplement, pharmaceutical, and animal health markets could impact financial performance.
  • Supply chain or production challenges in specialty ingredients may affect delivery and revenue.
  • Market volatility or broader economic conditions could influence investor response post-earnings release.

More from Press Releases

LPL Welcomes Allegia Wealth Management Jun 9, 2026 Businesses Race to Hire Claude Code Specialists As Demand Surges 938% Jun 9, 2026 Myseum.AI Announces Sponsorship and Panel Participation at Visual 1st 2026 Conference for Global Photo and Video industry Jun 9, 2026 KULR Technology Group Appoints New Chief Financial Officer and Independent Board Member Jun 9, 2026 Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium Jun 9, 2026